WO2010091299A3 - Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent - Google Patents

Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent Download PDF

Info

Publication number
WO2010091299A3
WO2010091299A3 PCT/US2010/023381 US2010023381W WO2010091299A3 WO 2010091299 A3 WO2010091299 A3 WO 2010091299A3 US 2010023381 W US2010023381 W US 2010023381W WO 2010091299 A3 WO2010091299 A3 WO 2010091299A3
Authority
WO
WIPO (PCT)
Prior art keywords
lyase inhibitor
combination
therapeutic agent
additional therapeutic
alpha
Prior art date
Application number
PCT/US2010/023381
Other languages
French (fr)
Other versions
WO2010091299A2 (en
Inventor
David Casebier
Scott C. Chappel
Original Assignee
Tokai Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokai Pharmaceuticals filed Critical Tokai Pharmaceuticals
Priority to GB1114153A priority Critical patent/GB2479337A/en
Priority to US13/146,001 priority patent/US20110319369A1/en
Publication of WO2010091299A2 publication Critical patent/WO2010091299A2/en
Publication of WO2010091299A3 publication Critical patent/WO2010091299A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17α-hydroxylase/C17,20-lyase inhibitor is administered to a subject in need thereof, including a subject with a refractory cancer and/or a subject currently undergoing another cancer treatment, wherein the 17α-hydroxylase/C17,20-lyase inhibitor is administered in combination with a therapeutically-effective amount of at least one additional therapeutic agent, including, but not limited to, another anti-cancer agent or a steroid.
PCT/US2010/023381 2009-02-05 2010-02-05 Novel combination cancer therapies WO2010091299A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1114153A GB2479337A (en) 2009-02-05 2010-02-05 Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US13/146,001 US20110319369A1 (en) 2009-02-05 2010-02-05 Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15002409P 2009-02-05 2009-02-05
US61/150,024 2009-02-05

Publications (2)

Publication Number Publication Date
WO2010091299A2 WO2010091299A2 (en) 2010-08-12
WO2010091299A3 true WO2010091299A3 (en) 2010-10-21

Family

ID=42154443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/023381 WO2010091299A2 (en) 2009-02-05 2010-02-05 Novel combination cancer therapies

Country Status (3)

Country Link
US (1) US20110319369A1 (en)
GB (2) GB2514957A (en)
WO (1) WO2010091299A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009129208A2 (en) * 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
AU2010210422A1 (en) 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
GB2479693B (en) * 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
CN102822190B (en) * 2009-11-13 2016-03-30 拓凯制药公司 Mammiferous steroid metabolism thing
KR101926320B1 (en) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 Combination therapy for the treatment of prostate carcinoma
EP2968219B1 (en) * 2013-03-14 2019-04-24 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP2991644B1 (en) * 2013-04-04 2020-03-25 University of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2016054472A1 (en) * 2014-10-02 2016-04-07 University Of Maryland, Baltimore Methods of treating pancreatic cancer
CN105732759A (en) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 Salt of 93beta)-17-(1H-benzimidazole-1-yl)androst-5,16-diene-3-ol and preparation method thereof
EP3503898A1 (en) * 2016-08-29 2019-07-03 California Institute of Technology Compositions and methods for treatment of prostate cancer
KR20220156177A (en) * 2021-05-18 2022-11-25 연세대학교 산학협력단 A composition for preventing, alleviating or treating cancer
KR20220156469A (en) * 2021-05-18 2022-11-25 연세대학교 산학협력단 A composition for preventing, alleviating or treating cancer
CN116444599A (en) * 2022-01-07 2023-07-18 中国科学院上海药物研究所 Steroid compound, preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200965B1 (en) * 1997-10-17 2001-03-13 The University Of Marylsnd, Baltimore 17-Azolyl steroids useful as androgren synthesis inhibitors
US20080280864A1 (en) * 2005-03-02 2008-11-13 University Of Maryland, Baltimore Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2008154382A1 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009120565A2 (en) * 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200965B1 (en) * 1997-10-17 2001-03-13 The University Of Marylsnd, Baltimore 17-Azolyl steroids useful as androgren synthesis inhibitors
US20010001099A1 (en) * 1997-10-17 2001-05-10 Angela Brodie Novel 17-azolyl steroids useful as androgen synthesis inhibitors
US20080280864A1 (en) * 2005-03-02 2008-11-13 University Of Maryland, Baltimore Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2008154382A1 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
WO2009120565A2 (en) * 2008-03-25 2009-10-01 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REID ALISON HM ET AL: "CYP17 inhibition as a hormonal strategy for prostate cancer.", NATURE CLINICAL PRACTICE. UROLOGY NOV 2008 LNKD- PUBMED:18985049, vol. 5, no. 11, November 2008 (2008-11-01), pages 610 - 620, XP008124318, ISSN: 1743-4289 *
SIMMONS M N ET AL: "Combined Androgen Blockade Revisited: Emerging Options for the Treatment of Castration-Resistant Prostate Cancer", UROLOGY, BELLE MEAD, NJ, US LNKD- DOI:10.1016/J.UROLOGY.2008.09.040, vol. 73, no. 4, 1 April 2009 (2009-04-01), pages 697 - 705, XP026060706, ISSN: 0090-4295, [retrieved on 20090130] *

Also Published As

Publication number Publication date
GB2514957A (en) 2014-12-10
WO2010091299A2 (en) 2010-08-12
GB201114153D0 (en) 2011-10-05
GB2479337A (en) 2011-10-05
GB201416433D0 (en) 2014-10-29
US20110319369A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
WO2010091299A3 (en) Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
TN2010000214A1 (en) Methods for treating obesity and obesity related diseases and disorders
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
MY160894A (en) Oligosaccharide composition for treating skin diseases
NZ604031A (en) Methods of treatment of pancreatic cancer
WO2010151755A3 (en) TREATMENT OF INFLAMMATORY DISEASES USING miR-124
MY161656A (en) Therapeutic use of diaminophenothiazines
WO2006052608A3 (en) Treatment of obesity and related disorders
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
NZ592786A (en) Methods and compositions for treating complement-associated disorders using eculizumab
WO2009128936A3 (en) Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
WO2011160062A3 (en) Compositions and methods for treating inflammatory conditions
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
TW200800975A (en) New compounds 2
WO2009074827A3 (en) Combination comprising a mek inhibitor and an aurora kinase inhibitor
WO2010059004A3 (en) Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
WO2010144336A3 (en) Methods for treating chronic kidney disease
WO2010014572A3 (en) Modulation of toll-like receptor 9 expression by antisense oligonucleotides
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
WO2009127414A3 (en) Inhibition of angiogenesis and tumor metastasis
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2008089070A3 (en) Combination therapy for the treatment of cancer
WO2007055743A3 (en) Treatment of obesity and related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10704282

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 1114153

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20100205

WWE Wipo information: entry into national phase

Ref document number: 1114153.8

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 13146001

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10704282

Country of ref document: EP

Kind code of ref document: A2